Skip to main content
Home
Articles
Latest Issue
Issue Archive
Special Issues
Supplements
Categories
Conference Correspondent
ASH 2023 - CLL
SABCS 2023 - HR+/HER2- MBC
Web Exclusives
All Web Exclusives
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor Instructions
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Policy
Advertise
Subscribe
Home
Articles
Latest Issue
Issue Archive
Special Issues
Supplements
Categories
Conference Correspondent
ASH 2023 - CLL
SABCS 2023 - HR+/HER2- MBC
Web Exclusives
All Web Exclusives
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor Instructions
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Policy
Advertise
Web Exclusives
FDA Oncology Update
FDA Approves Darzalex Faspro plus Pomalyst and Dexamethasone for Multiple Myeloma
Read More
FDA Oncology Update
FDA Approves Avapritinib for Advanced Systemic Mastocytosis
Read More
FDA Oncology Update
Pembrolizumab plus Lenvatinib Combination Receives Regular Approval for Advanced Endometrial Carcinoma
Read More
FDA Oncology Update
Padcev Receives Regular FDA Approval for Locally Advanced or Metastatic Urothelial Cancer
Read More
FDA Oncology Update
FDA Alert: Pepaxto (Melphalan Flufenamide) Associated with Increased Risk of Death in Postmarketing Clinical Trial
Read More
FDA Oncology Update
,
Breast Cancer
FDA Approves Margenza for Treatment of Metastatic HER2-Positive Breast Cancer
Read More
Cholangiocarcinoma
Emerging Molecular Targets in Cholangiocarcinoma: IDH1, HER2, BRAF, and Beyond
Read More
Cholangiocarcinoma
Combination of NUC-1031 plus Cisplatin Shows Promise as First-Line Treatment for Advanced Biliary Tract Cancer
Read More
Cholangiocarcinoma
FGFR Inhibition in Cholangiocarcinoma: Overcoming Acquired Resistance
Read More
Cholangiocarcinoma
Targeted Therapies in Cholangiocarcinoma: Next-Generation Sequencing Is a Must
Read More
2
3
4
5
6
7
8
Page 5 of 42
Results 41 - 50 of 417